Nilotinib HCl hydrate

Description: Nilotinib HCl hydrate (formerly also known as AMN-107, AMN107 HCl hydrate) is a potent, orally bioavailable aminopyrimidine-derivative Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. It is an FDA-approved drug for the treatment of imatinib-resistant chronic myelogenous leukemia. Nilotinib was designed based on the structure of imatinib and showed the superiority over imatinib in newly diagnosed or imatinib-resistant chronic myelogenous leukemia (CML). It was more potent than imatinib to wild-type BCR-ABL in a wide range of CML-derived and transfected cell lines. Nilotinib was also efficacious in gastrointestinal stromal tumors.

References: Blood. 2007; 109(5):2112-20. Epub 2006 Oct 26; J Hepatol. 2011; 55(3):612-25; Cancer Cell. 2005; 7:129-41.

Related CAS #: 923288-90-8 (HCl hydrate) 923288-95-3(HCl) 641571-10-0 (free base)